(Q44433738)

2 December 2017

title

Introduction: Institutional corruption and the pharmaceutical policy (English)

1 reference

2 December 2017

Marc A Rodwin

1

1 reference

2 December 2017

publication date

1 January 2013

1 reference

Journal of Law, Medicine, and Ethics

2 December 2017

published in

1 reference

2 December 2017

volume

41

1 reference

2 December 2017

issue

3

1 reference

2 December 2017

page(s)

544-552

1 reference

Pharmaceuticals, political money, and public policy: a theoretical and empirical agenda

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12062

Corruption of pharmaceutical markets: addressing the misalignment of financial incentives and public health

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12062

Five un-easy pieces of pharmaceutical policy reform.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12062

Institutional corruption of pharmaceuticals and the myth of safe and effective drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12062

From bad pharma to good pharma: aligning market forces with good and trustworthy practices through accreditation, certification, and rating

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12062

Understanding pharmaceutical research manipulation in the context of accounting manipulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12062

Curbing misconduct in the pharmaceutical industry: insights from behavioral ethics and the behavioral approach to law.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12062

The ethics of pharmaceutical research funding: a social organization approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12062

Key opinion leaders and the corruption of medical knowledge: what the Sunshine Act will and won't cast light on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12062

Drug firms, the codification of diagnostic categories, and bias in clinical guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12062

Rooting out institutional corruption to manage inappropriate off-label drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12062

Physicians under the influence: social psychology and industry marketing strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12062

From community to commodity: the ethics of pharma-funded social networking sites for physicians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12062

Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJLME.12062

21 January 2018

Identifiers

DOI

10.1111/JLME.12062

1 reference

2 December 2017

1 reference